Albert Hazan, MD
Ophthalmology · Brooklyn, NYNPI 1427491265
Payments from drug & device makers
Across 343 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$841
- Bausch & Lomb Americas Inc.$659
- Harrow Eye, LLC$237
- Dompe US, Inc.$231
- Mallinckrodt Hospital Products Inc.$219
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,94399%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 90 | $1,649 |
| AbbVie(2 entities) | 53 | $841 |
| Bausch & Lomb Americas Inc. | 52 | $659 |
| Harrow Eye, LLC | 16 | $237 |
| Dompe US, Inc. | 15 | $231 |
| Mallinckrodt Hospital Products Inc. | 12 | $219 |
| Eyevance Pharmaceuticals LLC | 10 | $197 |
| Thea Pharma Inc. | 11 | $194 |
| NEW World Medical,inc. | 3 | $186 |
| Tarsus Pharmaceuticals, Inc. | 11 | $185 |
| Novartis | 9 | $183 |
| Akorn Operating Company LLC | 13 | $178 |
| Baxter Healthcare | 1 | $148 |
| Sight Sciences, Inc. | 6 | $115 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $110 |
| Astellas Pharma US Inc | 5 | $101 |
| Oyster Point Pharma, Inc. | 5 | $96 |
| Ivantis, Inc | 5 | $84 |
| Kala Pharmaceuticals, Inc. | 4 | $76 |
| Sun Pharmaceutical Industries Inc. | 3 | $66 |
| Amgen(2 entities) | 3 | $62 |
| Akorn, Inc. | 3 | $62 |
| Biotissue Holdings Inc. | 2 | $38 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $27 |
| Iridex Corporation | 1 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Rayner Intraocular Lenses Limited | 1 | $19 |
| Beaver-visitec International, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon PanOptix Pro$146
- Clareon$141
How this compares
$6,023 in reported general payments places this provider in the 80th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 181 | $146,268 |
| LumiganBimatoprost | 227 | $104,091 |
| CombiganBrimonidine Tartrate/Timolol | 220 | $83,332 |
| VyzultaLatanoprostene Bunod | 167 | $69,401 |
| XiidraLifitegrast | 60 | $40,120 |
| Brimonidine Tartrate | 518 | $37,391 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 174 | $35,237 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 193 | $31,639 |
| Cyclosporine | 89 | $31,054 |
| Alphagan PBrimonidine Tartrate | 92 | $28,556 |
| RocklatanNetarsudil Mesylat/Latanoprost | 56 | $24,369 |
| Brinzolamide | 130 | $24,157 |
| Prednisolone Acetate | 718 | $21,757 |
| TyrvayaVarenicline Tartrate | 28 | $18,077 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,193 | $17,881 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $841 | $362,246720 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $659 | $123,814246 claims |
| AlconSimbrinza, Azopt | $1,649 | $46,199203 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $96 | $18,07728 claims |
| Thea Pharma Inc.Iyuzeh | $194 | $8,80227 claims |
| Eyevance Pharmaceuticals LLCZerviate | $197 | $8,53624 claims |
| Akorn, Inc.Zioptan | $62 | $5,89921 claims |
| NovartisTravatan Z | $183 | $5,12416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Brooklyn
- David RubaltelliBrooklyn$8.9M
- Irene GladsteinBrooklyn$250K
- Douglas JabsNew York$24.3M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.